ライフサイエンスコーパス: bone tumor

1 clinical outcomes in the surgical removal of bone tumor.

2 blation has been widely accepted in treating bone tumor.

3 microwave-induced hyperthermia to remove the bone tumor.

4 s the second most common malignant pediatric bone tumor.

5 en, and only two of the G2A-R mice developed bone tumors.

6 hat SV40-like sequences are present in human bone tumors.

7 sions that have similarities to human FD and bone tumors.

8 activity and did not affect the phenotype of bone tumors.

9 heir indications to the treatment of primary bone tumors.

10 odality therapy for the treatment of primary bone tumors.

11 al study is the survivors of lower-extremity bone tumors.

12 er than 8 cm in diameter, and 26 had primary bone tumors.

13 imb salvage procedures for primary malignant bone tumors.

14 esions from more common, aggressive temporal bone tumors.

15 analyzable in 316 patients: 183 had primary bone tumors; 133 had primary soft-tissue tumors.

16 beled targeted Pam-NPs demonstrated enhanced bone tumor accumulation and prolonged retention compared

17 is the second most common primary malignant bone tumor and highly resistant to conventional chemothe

18 vivo models for investigating human primary bone tumors and cancer metastasis to the bone rely on th

19 ave proved effective for treatment of benign bone tumors and for palliation of metastases involving b

20 a is a heterogeneous collection of malignant bone tumors and is the second most common primary malign

21 steolysis associated with inoperable primary bone tumors and multifocal skeletal metastases remains a

22 FGF9-neutralizing antibody developed smaller bone tumors and reduced bone formation.

23 ems to be of benefit in T-staging of primary bone tumors and soft-tissue sarcomas.

24 the major surgical approaches to lower-limb bone tumors and their impact on pediatric patients.

25 acture, basilar impression, spinal stenosis, bone tumor, and osteoarthrosis.

26 curred both in vivo in experimental prostate bone tumors, and in vitro in co-cultures of bone marrow

27 These include primary bone tumors as well as metastatic disease from distant p

28 treated versus untreated metastatic prostate bone tumors at 7 days post treatment initiation (P < 0.0

29 mportant clinical factor in the diagnosis of bone tumors, because various lesions have predilections

30 oblastoma, soft-tissue sarcoma, or malignant bone tumor before the age of 21 years and who survived a

31 disability include an original diagnosis of bone tumor, brain tumor, or Hodgkin's disease; female se

32 ng in breast cancer cells therefore promotes bone tumor burden and tumor-mediated osteolysis through

33 e chemotherapeutic docetaxel, we showed that bone tumor burden could be reduced significantly with le

34 C)-mediated T-cell activation, had increased bone tumor burden despite protection from bone loss.

35 In a model of tumor metastasis to bone, bone tumor burden was decreased in the CD47(-/-) mice co

36 gulates processes associated with osteolytic bone tumor burden, we stably infected the bone-seeking M

37 To invade the bone, tumor cells produce osteoclast-activating factors

38 bone cyst (ABC) is an aggressive, pediatric bone tumor characterized by extensive destruction of the

39 Osteosarcoma (OS) is the most common bone tumor characterized with a high risk of amputation

40 he approach to the radiographic diagnosis of bone tumors consists of analyzing the lesion in an organ

41 Primary bone tumors constitute 1-1.5% of all tumors, and 7% of a

42 ion of the tumors reveals that the FBR v-fos bone tumors contain malignant cells with features of fou

43 ance in selected cases--for example, primary bone tumors, early bone marrow infiltration, and tumors

44 long-term complications in primary malignant bone tumors for the pediatrician caring for a child with

45 Ewing's sarcoma is a highly malignant bone tumor found in children and adolescents, and the or

46 Histopathological analyses of bone tumors generated by PDGF-D-expressing LNCaP cells (

47 D in human PCa LNCaP cells leads to enhanced bone tumor growth and bone responses in immunodeficient

48 Finally, enhancement of bone tumor growth in the absence of CXCR4 was abrogated

49 d apoptosis in 2 in vivo syngeneic models of bone tumor growth in which apoptosis-inducible prostate

50 tion treatment significantly inhibited C4-2B bone tumor growth, and the results were correlated with

51 to the effects of G-CSF administration upon bone tumor growth.

52 However, its role in primary bone tumors has not been established.

53 were significantly increased for subsequent bone tumors (HR, 1.60; 95% CI, 1.03 to 2.49) and leiomyo

54 ma (OS) is the most common primary malignant bone tumor in children, and microRNA-34a (miR-34a) repla

55 Osteosarcoma is the most common malignant bone tumor in children.

56 Osteosarcoma is the most common malignant bone tumor in dogs and, like its human orthologue, is ch

57 Ewing sarcoma is the most lethal bone tumor in young patients and arises from primitive s

58 ma are the two most common primary malignant bone tumors in children and account for approximately 6%

59 nts have been developed for the treatment of bone tumors in growing children.

60 sts was sufficient to drive the formation of bone tumors, including OS, with complete penetrance.

61 hologic fracture (P = .03) and percentage of bone-tumor interface (BTI) ablated (P = .02).

62 administration improved bone quality at the bone-tumor interface and, surprisingly, increased histol

63 in-6 and the p65 subunit of NF-kappaB at the bone-tumor interface.

64 ent, osteoclast numbers were elevated at the bone/tumor interface in the vehicle-treated mice compare

65 Percutaneous biopsy of primary bone tumors is safe and accurate for diagnosis and grade

66 eosarcoma, the most common pediatric primary bone tumor, is an aggressive malignancy with a tendency

67 of ten 5-FC-treated Tg/NCD mice had complete bone tumor killing and five of six 5-FC-treated Tg/NCD-C

68 teolytic and tumor cell-driven events in the bone-tumor microenvironment.

69 h osteoclasts and are critical components of bone-tumor microenvironment; however, their function in

70 rcoma (ES), the second most common malignant bone tumor of childhood.

71 In 33 patients 2-51 mo after resection of a bone tumor of the limbs, a total of 42 dynamic PET scans

72 dverse health status domain among those with bone tumors (OR, 2.1; 95% CI, 1.8-2.5; P<.001), central

73 Primary bone tumors, osteosarcomas and chondrosarcomas, derive f

74 erved in patients who presented with primary bone tumors (P = .016).

75 stantially better survival for patients with bone tumors, particularly pediatric patients.

76 rotocol provided a powerful tool to evaluate bone tumor progression in a rat model of bone metastasis

77 of this study was to longitudinally monitor bone tumor progression using PET/MR image coregistration

78 gesics, quality of life, performance status, bone tumor response, and biochemical parameters were als

79 PC3 and LNCaP bone tumors showed a desmoplastic stromal response, whic

80 nancies included thyroid cancer (SIR, 36.4), bone tumors (SIR, 37.1), and colorectal (SIR, 36.4), lun

81 y decreased 99mTc-MDP activity at metastatic bone tumor sites.

82 This review addresses PET/MRI of bone tumors, soft-tissue sarcoma, melanoma, and lymphoma

83 than 17.8 years (> or =28.0%) for brain and bone tumor survivors, and was sensitive to late-recurren

84 Chordoma is a rare malignant bone tumor that expresses the transcription factor T.

85 OS) is the most frequent pediatric malignant bone tumor that has a high propensity for metastases.

86 Osteosarcoma (OS) is a primary bone tumor that is most prevalent during adolescence.

87 Osteosarcoma is the bone tumor that most commonly affects children, adolesce

88 smal bone cysts (ABC) are locally aggressive bone tumors that often feature chromosome 17p13 rearrang

89 utcome and physical activity after intensive bone tumor treatment.

90 undred ten consecutive patients with primary bone tumors underwent biopsy with computed tomography (C

91 However, when grown in bone, tumor volume was decreased in OPG-C4-2 versus pcDN

92 Applications in pulmonary, renal, and bone tumors were also discussed.

93 Of these patients, benign bone tumors were better defined with surgical specimens

94 ors were primarily osteolytic, whereas LNCaP bone tumors were both osteoblastic and osteolytic.

95 PC3 and DU145 bone tumors were primarily osteolytic, whereas LNCaP bon

96 Bone tumors were subcultured, and chromosomal analysis d

97 Additional DNA samples from bone tumors were then analysed.

98 L-1R are significantly less prone to develop bone tumors when inoculated in the arterial circulation

99 Chondrosarcoma is a primary bone tumor with a dismal prognosis; most patients with t

100 Osteosarcoma is a common malignant bone tumor with a propensity to metastasize to the lungs

101 ice develop osteosarcoma (OS), an aggressive bone tumor with poor prognosis that often metastasizes t

102 f treated animals had complete regression of bone tumors with no development of lytic bone lesions.

103 Osteosarcoma is the most common primary bone tumor, with metastatic disease responsible for most

104 Inhibiting HER2 expression in bone tumor xenografts reduced proliferation and RANK exp

105 Osteosarcoma is the most common primary bone tumor, yet there have been no substantial advances